BridgeBio Pharma Shares Are Trading Higher After the Company Announced That the FDA Approved Attruby to Treat Adults With ATTR-CM. Also, HC Wainwright Maintained a Buy Rating on the Stock and Raised Its Price Target From $43 to $49.
BridgeBio Pharma Shares Are Trading Higher After the Company Announced That the FDA Approved Attruby to Treat Adults With ATTR-CM. Also, HC Wainwright Maintained a Buy Rating on the Stock and Raised Its Price Target From $43 to $49.
bridgebio pharma的股票在公司宣佈FDA批准Attruby用於治療成人ATTR-Cm後上漲。此外，HC Wainwright維持了對該股票的買入評級，並將其目標價格從43美元提高到49美元。
BridgeBio Pharma Shares Are Trading Higher After the Company Announced That the FDA Approved Attruby to Treat Adults With ATTR-CM. Also, HC Wainwright Maintained a Buy Rating on the Stock and Raised Its Price Target From $43 to $49.
BridgeBio Pharma宣佈美國食品藥品管理局批准Attruby使用Attr-CM治療成年人後，該公司股價走高。此外，HC Wainwright維持了該股的買入評級，並將其目標股價從43美元上調至49美元。
資訊熱榜
更新時間